About the BreastSentry Test

BreastSentry measures the levels of two biomarkers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman’s risk for developing breast cancer. Elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer (1-5). BreastSentry provides women with additional information about breast health beyond mammography. Women with elevated BreastSentry scores may need to be referred for advanced imaging tests, such as breast MRI or Ultrasound in addition to a screening mammogram.

BreastSentry needs to be prescribed by a physician and is available through AVRT, StageZero’s comprehensive telehealth program that uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages.  Whether you have a family history of cancer or are simply concerned about developing cancer, our physicians can work with you to develop a patient-centric, personalized care plan to help optimize your health.

Contact Us To Get Started!

This field is for validation purposes and should be left unchanged.

BreastSentry is for any woman who needs further evaluation of breast cancer risk. 
The BreastSentry Test is intended for use in women without a personal history of breast cancer. Patients with a known history of impaired renal function are not candidates for the BreastSentry test.

AVRT is a New, Revolutionary Approach to Healthcare!

AVRT is a comprehensive, physician supervised telehealth program which uses advanced diagnostics to help detect cancer and chronic disease in the earliest stages when they are highly treatable, along with lifestyle and pharmaceutical management.

Contact Us To Get Started!

This field is for validation purposes and should be left unchanged.

Our Physicians Are Leaders in the Field of Cancer 

In order to help prevent cancer, we first must understand cancer and how it functions. That’s why AVRT is led by leading oncologists, who can provide insights into nutrition, lifestyle modifications and medications to help minimize your risk of developing cancer. AVRT physicians and scientists are experts in the field of cancer, inflammation and metabolism and develop patient-centric, personalized care plans to optimize patient health. We are committed to the singular goal of prevention: keeping people healthy and reducing the risk of cancer & chronic disease. ​Meet a few of our physicians below.tween.

Charles J. Meakin, MD, MHA

Charles J. Meakin, III, M.D., MHA received his medical degree from the University of Cincinnati College of Medicine, followed by a residency in Radiation Oncology at Stanford University Medical Center, Stanford, CA. Board Certified in Radiation Oncology, he also completed a Masters in Health Administration from St. Mary’s College of Moraga, Moraga, CA.

Christy M. Kesslering, M.D.

Christie Kesslering, M.D. received her medical degree from the Stritch School of Medicine, Loyola University, Maywood, IL, followed by a residency in Radiation Oncology at the University of Wisconsin, Madison, WI. She is Board Certified in Radiation Oncology.

Zoraida Mendez, M.D.

Zoraida Mendez, M.D. received her medical degree at Universidad Nacional Pedro Henriquez Urena, Santo Domingo, Dominican Republic,  followed by a residency in Internal Medicine at Saint Elizabeth Hospital of Youngstown, OH. She completed her Fellowship in Hematology and Oncology at the Cleveland Clinic Foundation in Cleveland, Ohio.

Paul Zhang, M.D., Ph.D

Paul Zhang, M.D., Ph.D. is a physician-scientist board-certified in medical oncology and internal medicine. Dr. Zhang received his medical degrees from Hebei Medical University and Beijing University. He completed his residency in Internal Medicine at Columbia University, New York, NY, a Clinical Fellowship at Yale University, New Haven, CT and a Cancer Research Fellowship at Memorial Sloan-Kettering Cancer Center, New York, NY.

What Kinds of Testing Do You Offer?

AVRT works with StageZero Life Sciences, a CLIA Certified, CAP Accredited High Complexity Laboratory in Richmond, VA to provide the most advanced testing for early cancer detection. Tests available through Stage Zero include:

AVRT Panel

A comprehensive panel including inflammatory markers and metabolic function tests to help identify early warning signs of chronic disease and metabolic conditions.  ​


Aristotle is a blood-based mRNA Multi-Cancer Panel for Identifying the molecular signatures of multiple cancers from a single blood draw(6)


ColonSentry® is a blood test that uses advanced mRNA gene expression technology to help identify Colorectal Cancer (CRC) early when it’s most treatable (7).


BreastSentry is a blood test that can help identify if a woman has an increased risk for developing breast cancer (3).


The Prostate Health Index is an FDA approved blood test that can help men with elevated PSA to differentiate benign prostate conditions from prostate cancer (8,9).

How it works

Fill out any of the contact forms above to set up a FREE consult with a case manager to learn more about the test.

  1. Tell us more about you by completing a health profile form prior to your first call with a physician.
  2. Attend your initial consultation with a physician to review your medical records, concerns and goals.
  3. Get tested, receive your test results and review with an AVRT physician.

Should you choose to move into our AVRT program, you’ll get an individualized care plan to help you continue your journey to health.


  1. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469 
  2. O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.  Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6. 
  3. Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8 
  4. Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78 
  5. Dupouy S, Viardot-Foucault V, Alifano M,  et al.  The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE 2009; 4(1): e4223. https://doi.org/10.1371/journal.pone.0004223 ​
  6. Dempsey A, Chao S, Stamatiou D, et al., Aristotle: A single blood test for pan-cancer screening. Journal of Clinical Oncology. 2020; 38:15_suppl, e15037-e15037
  7. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
  8. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
  9. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169

​The BreastSentry Test is intended for use in women without a personal history of breast cancer. Patients with a known history of impaired renal function are not candidates for BreastSentry. ‡The pro-NT® and pro-ENK® biomarkers are licensed from sphingotec GmbH. The BreastSentry test was developed and its performance characteristics were determined by StageZero Life Sciences Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is for clinical purposes. It should not be regarded as investigational or for research. This test must be ordered by and used only in consultation with a healthcare provider. This laboratory is certified under CLIA as qualified to perform high complexity clinical laboratory testing.

Aristotle, ColonSentry, & BreastSentry tests were developed, and their performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration. These tests were performed in a CLIA certified laboratory and are intended for clinical purposes. The Aristotle, Prostate Health Index, ColonSentry, & BreastSentry tests must be ordered by and used only in consultation with a healthcare provider.